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Abstract
Introduction: To investigate whether monosodium urate (MSU) crystals induce the production of CCL2 (monocyte 
chemoattractant protein-1; MCP-1) in human fibroblast-like synoviocytes (FLS) and whether this mechanism would be 
affected by high-density lipoproteins (HDL).
Methods: Human FLS isolated from synovial tissue explants were stimulated with MSU crystals (0.01 to 0.5 mg/ml) or 
interleukin (IL)-1β (10 pg/ml) in the presence or absence of HDL (50 and 100 μg/ml). The production and expression of 
CCL2 was evaluated with ELISA, confocal microscopy, immunofluorescence microscopy, chemotaxis assay, and real-
time quantitative PCR.
Results: Exposure of FLS to MSU crystals induced CCL2 accumulation in culture medium in a dose- and time-
dependent manner, reaching a plateau at 50 to 75 μg/ml MSU crystals and 20 to 24 hours. Although low, the induced 
CCL2 levels were sufficient to trigger mononuclear cell migration. In resting FLS, CCL2 was localized in small 
cytoplasmic vesicles whose number diminished with MSU crystal stimulation. Concomitantly, MSU crystals triggered 
the induction of CCL2 mRNA expression. All these processes were inhibited by HDL, which cause a 50% decrease in 
CCL2 mRNA levels and a dose-dependent inhibition of the release of CCL2. Similar results were obtained when FLS 
were pretreated with HDL and washed before activation by MSU crystals or IL-1β, suggesting a direct effect of HDL on 
the FLS activation state.
Conclusions: The present results demonstrate that MSU crystals induce FLS to release CCL2 that is stored in vesicles in 
resting conditions. This mechanism is inhibited by HDL, which may limit the inflammatory process by diminishing CCL2 
production and, in turn, monocytes/macrophages recruitment in joints. This study confirms the antiinflammatory 
functions of HDL, which might play a part in the limitation of acute gout attack.
Introduction
CCL2 (monocyte chemoattractant protein-1; MCP-1), a
member of the C-C chemokine family, is a major monocyte
chemoattractant [1]. CCL2 production is inducible in vari-
ous types of cells, including synoviocytes [2,3]. In vivo
studies suggest that CCL2 attracts monocytes to sites of
inflammation in a variety of pathologic conditions, includ-
ing atherosclerosis [4,5], pulmonary fibrosis and granu-
lomatous lung disease [6], and degenerative and
inflammatory arthropathies, including gout [7-9]. Gout is a
consequence of elevated serum urate levels that lead to
deposition of monosodium urate (MSU) crystals in joints,
causing an acute inflammatory response [10]. MSU crystals
are indeed potent inducers of inflammation, as demon-
strated in vivo. When injected into the peritoneum or in the
air pouch of animal models, MSU crystals induce an
inflammatory response characterized by a cellular infiltrate
rich in neutrophils and the production of proinflammatory
cytokines, as well as other inflammatory mediators, includ-
ing CCL2 [11-13]. CCL2 has long been associated with
crystal inflammation. Elevated levels of CCL2 were mea-
sured in synovial fluid of gout patients [14]. Besides, in
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gouty arthritis models, intraarticular injection of MSU crys-
tals induces the rapid release of CCL2 within 1 hour after
injection, reaching a maximum at 2 to 4 hours [7]. Thus,
CCL2 might be involved in the recruitment of monocytes/
macrophages at the site of inflammation.
Once infiltrated in the joints, MSU crystals trigger mono-
cytes/macrophages to produce IL-1β, a mechanism highly
relevant to gout, the acute form of which is effectively
treated with the recombinant form of IL-1-receptor antago-
nist, a specific IL-1 inhibitor [15,16]. Although the pres-
ence of MSU crystal-specific receptor at the cell surface is
unlikely, MSU crystals might stimulate cells through mem-
brane lipid alteration [17].
By secreting CCL2, activated resident synoviocytes may
display the ability to recruit monocytes into the joints and,
in turn, to set in the inflammatory response that underlies
the acute attack of gout. In most cases, the acute attack is
self-limited by processes that remain largely unknown [18].
However, a number of plasma proteins and lipoproteins that
suppress the MSU crystals deleterious effects have been
identified in synovial fluids. Among them, apolipoprotein
(apo) B and apo E inhibit crystal-induced neutrophil stimu-
lation by binding to the surface of crystals [19,20]. In addi-
tion, low-density lipoproteins (LDL) and high-density
lipoproteins (HDL) strongly inhibit calcium and MSU crys-
tal-induced neutrophil cytolysis [21], and LDL contribute
to the resolution of acute inflammatory attack induced by
calcium crystals in the rat air-pouch model [22]. Recently,
we demonstrated that HDL-associated apo A-I can exert
antiinflammatory effects through the inhibition of cytokine
production in monocytes/macrophages on contact with
stimulated T cells or with stimulated T cell-derived
microparticles [23,24]. Together, these studies suggest that
lipoproteins may act at several levels to dampen inflamma-
tion.
Because MSU crystals increase CCL2 expression in vas-
cular smooth muscle and epithelial cells [25,26], this study
was undertaken to assess whether MSU crystals might dis-
play similar activity toward fibroblast-like synoviocytes
(FLS), and whether this activity might be modulated by
HDL. The results show that FLS contain stores of CCL2
that are released on activation by MSU crystals. Further-
more, MSU crystals also induce CCL2 gene transcription to
refurbish stores. Both these MSU-crystal activities are
inhibited in the presence of HDL.
Materials and methods
Human materials
Human synovial tissue from patients and blood from
healthy volunteers was obtained with the approval of the
Institutional Review Board of the University of Padova,
which approved the study. An informed-consent form was
signed by the patients and volunteers.
FLS isolation and culture
Synovial tissue specimens were obtained from three
osteoarthritis patients undergoing surgical joint replace-
ment. FLS were isolated from tissue explants, as previous
described [27]. In brief, synovium samples were rinsed sev-
eral times in PBS, minced into ~1-mm pieces, placed in
T25 flasks (Falcon, Oxnard, CA, USA), and maintained in
DMEM supplemented with 10% heat-inactivated fetal calf
serum (FCS), 50 μg/ml streptomycin, 50 U/ml penicillin,
and 2 mmol/L glutamine (10% FCS medium). At conflu-
ence, cells were harvested (trypsin/EDTA) and seeded into
new flasks. All experiments were carried out with passage 4
through 8 FLS. FLS were CD90+, CD55+, and were posi-
tive for prolyl-4-hydroxylase, as demonstrated by immuno-
cytochemical staining with specific antibodies (Chemicon
International, Temecula, CA, USA). FLS were seeded in
96-well culture plates at a density of 1 × 104 cells/well,
unless otherwise stated. Cells were allowed to adhere for 24
hours, and then the medium was exchanged for a medium
supplemented with 2% FCS and the indicated concentration
of MSU crystals and HDL. Cell viability was assayed with
trypan blue exclusion staining and was found to be higher
than 98% in basal conditions.
Isolation of HDL
Human serum HDL were isolated, and their protein content
quantified, as previously described [23].
Synthesis of MSU crystals
MSU crystals were prepared as described by Denko and
Whitehouse [28]. In brief, 4 g uric acid was dissolved in
800 ml of deionized water, heated to 60°C, adjusted to pH
8.9 with 0.5 N NaOH, and let crystallize overnight at room
temperature. MSU crystals were recovered by centrifuga-
tion, washed with distilled water and dried at 40°C for 24
hours. Crystal shape and birefringence were assessed by
compensated polarized light microscopy. MSU crystals
were milled and then sterilized by heating at 180°C for 2
hours before each experiment. Less than 0.015 EU/ml
endotoxin were measured in MSU crystal preparations by
Limulus amebocyte lysate assay (E-toxate kit, Sigma-
Aldrich S.r.l., Milano, Italy).
Cytokines production
FLS were stimulated by MSU crystals in DMEM supple-
mented with 2% heat-inactivated FCS, 50 μg/ml streptomy-
cin, 50 U/ml penicillin, 2 mmol/L glutamine, 5 μg/ml
polymyxin, and filtered before the use (2% FCS medium).
HDL were added with or 1 hour before stimulation by MSU
crystals. Culture supernatants were harvested and stored at -
20°C before CCL2, IL-8, and IL-1β measurements by
enzyme immunoassay (RayBiotech, Inc., Norcross, GA,
USA). Cytotoxicity of MSU crystals and HDL was
assessed with a colorimetric assay for cell proliferation andScanu et al. Arthritis Research & Therapy 2010, 12:R23
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activity (MTT, Chemicon International, Temecula, CA,
USA), which measures mitochondrial activity of cells. In
some experiments, cells were pretreated with 10 μg/ml
cycloheximide (CHX; Sigma-Aldrich S.r.l., Milano, Italy)
for 30 minutes before stimulation. Alternatively, FLS were
stimulated by IL-1β (Recombinant Human IL-1β; R&D
systems, Minneapolis, MN, USA). Inhibition experiments
were carried out with IL-1-receptor antagonist (IL-1Ra,
R&D Systems, Minneapolis, MN, USA).
Confocal microscopy
FLS were grown in eight-well chamber slides at a density
of 2 × 104 cells/well in 10% FCS medium and then were
incubated with MSU crystals (50 μg/ml) or HDL (50 and
100 μg/ml) or both for 24 hours in 2% FCS medium. Cells
were washed 3 times in PBS, fixed with 4% paraformalde-
hyde for 10 minutes, and permeabilized with 0.1% Triton
X-100 in PBS for 4 minutes at 4°C. After washing and
blocking with 2% BSA for 30 minutes at room temperature,
cells were incubated for 1 hour with anti-CCL2 mAb (R&D
systems, Minneapolis, MN, USA) diluted 1:20 in blocking
buffer. After washing, bound antibodies were detected by
using Alexa Fluor 488-conjugated goat anti-mouse IgG sec-
ondary Ab (1:150; Invitrogen S.R.L., San Giuliano Mila-
nese, Italy) for 30 minutes at room temperature in the dark.
Samples were analyzed with confocal microscopy (2100
Multiphoton; Bio-Rad Laboratories, Inc., Italy), by using
laser excitation at 488 nm.
Chemotaxis assay
Mononuclear cells were isolated from peripheral blood
from healthy volunteers by density gradient centrifugation
with Histopaque 1077 (Sigma-Aldrich S.r.l., Milano, Italy).
The effects of MSU crystals and HDL on the chemotaxis of
mononuclear cells were assessed by using a 48-well modi-
fied Boyden chamber (AC48; NeuroProbe, Bethesda, MD,
USA). Culture supernatants of FLS stimulated by MSU
crystals in the presence or absence of HDL were loaded in
the bottom chamber, and mononuclear cells were added to
the top chamber. DMEM was used as a negative control,
and 10 ng/ml CCL2 (RayBiotech, Inc., Norcross, GA,
USA) was used as a positive control. A polyvinylpyrroli-
done-free polycarbonate 8-mm membrane with 5-μm pores,
pretreated with 10 μg/ml fibronectin, was placed between
the chambers. In brief, 28-μl aliquots of culture superna-
tants were dispensed into the bottom wells of the chamber.
Fifty-microliter aliquots of mononuclear cells (1 × 106 cells/
ml) resuspended in RPMI 1640 were added to the top wells.
Chambers were incubated at 37°C with 5% CO2 for 2 hours.
The membrane was then removed, washed with PBS on the
upper side, fixed, and stained with DiffQuik (Baxter Scien-
tific, Miami, FL, USA). Cells were counted microscopi-
cally at ×1,000 magnification in four fields per membrane.
All assays were performed in duplicate.
CCL2 mRNA
FLS were grown to confluence in six-well culture dishes in
10% FCS medium and then incubated with MSU crystals
(50 μg/ml) in the presence or absence of HDL (100 μg/ml)
for the indicated time periods in 2% FCS medium. Superna-
tants were harvested for CCL2 measurements, and total
FLS RNA was prepared by Tri?Reagent, as described by
the provider (Sigma-Aldrich S.r.l., Milano, Italy). Quantita-
tive real-time duplex PCR analysis (TaqMan quantitative
ABI PRISM 7300 Detection System, Applied Biosystems)
was conducted after reverse transcription by SuperScript II
(Invitrogen S.R.L., San Giuliano Milanese, Italy). The lev-
els of mRNA expression were normalized, with the expres-
sion of a housekeeping gene (18S) analyzed
simultaneously. CCL2 and 18S probes were purchased from
Applied Biosystems. All measurements were conducted in
triplicate.
Statistical analysis
When required, data significance was assessed with Stu-
dent's t test; P < 0.05 was considered significant.
Results
MSU crystals induce CCL2 release by human FLS
To evaluate the capacity of MSU crystals to induce CCL2
release, FLS were incubated for 24 hours with increasing
concentrations of MSU crystals. In the range of concentra-
tions used, MSU crystals did not significantly affect cell
viability, which was only slightly decreased at concentra-
tions higher than 50 μg/ml (data not shown). In the absence
of stimulus, FLS released low but significant levels of
CCL2 amounting to 55 ± 20 pg/ml (Figure 1a). A similar
pattern of CCL2 production was observed among FLS
preparations, independent of the donor or cell passage,
although the extent of CCL2 production varied between
experiments, as indicated by the error bar dimension (Fig-
ure 1). MSU crystals induced a dose-dependent increase of
CCL2 production in FLS, reaching a plateau at 50 to 75 μg/
ml MSU crystals (Figure 1a). To determine the time
required for maximal chemokine production, FLS were
exposed to 50 μg/ml MSU crystals for increasing time peri-
ods. As depicted in Figure 1b, CCL2 production reached a
plateau at 20 to 24 hours. Therefore, in the experiments
described later, FLS were activated for 24 hours with an
optimal dose of 50 μg/ml of MSU crystals. Because FLS
might release IL-1, a potent stimulus of fibroblasts, FLS
were stimulated by MSU crystals in the presence of the IL-
1-specific inhibitor, IL-1Ra [29]. As shown in Figure 1c,
the production of CCL2 induced by MSU crystals was not
affected by 250 ng/ml IL-1Ra. In the same experiments,
such an IL-1Ra dose abolished CCL2 production induced
by 125 pg/ml IL-1β (Figure 1d). IL-1Ra per se had no
effect on CCL2 production by FLS (Figure 1c and 1d).
These results demonstrate that the production of CCL2 wasScanu et al. Arthritis Research & Therapy 2010, 12:R23
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directly induced by MSU crystals, ruling out the participa-
tion of an autocrine loop of IL-1.
CCL2 is contained in small vesicles in FLS
Because CCL2 is constitutively contained in small storage
granules within endothelial cell cytoplasm [30,31], the
presence of such a compartment was assessed in FLS with
confocal microscopy. In resting FLS, CCL2 was localized
in small vesicles in cell cytoplasm (Figure 2a). Consistent
with CCL2 release, after 24-hour stimulation with 50 μg/ml
MSU crystals, a marked diminution of the number of
CCL2-containing vesicles was observed as compared with
unstimulated cells (Figure 2b). These data suggest that FLS
contained intracellular pools of CCL2 that was stored in
small vesicles and thus might be rapidly released on stimu-
lation.
HDL inhibit MSU crystal-induced CCL2 production in FLS
To assess the antiinflammatory activity of HDL, FLS were
incubated with MSU crystals in the presence or absence of
50 or 100 μg/ml HDL for 24 hours. As shown in Figure 3a,
HDL significantly decreased the MSU crystal-induced
CCL2 production in a dose-dependent manner. This inhibi-
tion was not due to the formation of complexes between
Figure 1 Effect of monosodium urate (MSU) crystals on CCL2 production in cultured fibroblast-like synoviocytes (FLS). (a) FLS were treated 
with increasing concentrations of MSU crystals for 24 hours. (b) Synoviocytes were incubated in the presence (black circles) or absence (white circles) 
of 50 μg/ml MSU crystals for the indicated time. CCL2 was measured in culture supernatants with ELISA. Results are presented as mean ± SD of three 
separate experiments. (c) FLS were stimulated (grey columns) or not (white columns) for 24 hours with 50 μg/ml MSU crystals in the presence or ab-
sence of 250 ng/ml IL-1Ra. IL-1Ra was either added with MSU crystals (MSU + IL-1Ra) or added to FLS 1 hour before activation by MSU crystals (IL-1Ra 
+ MSU). (d) FLS were stimulated (black columns) or not (white columns) for 24 hours with 125 pg/ml IL-1β in the presence or absence of 250 ng/ml 
of IL-1Ra. IL-1Ra was either added with IL-1β (IL-1β + IL-1Ra) or added to FLS 1 hour before activation by IL-1β (IL-1Ra + IL-1β). (c, d) Culture superna-
tants were analyzed for the production of CCL2. Results are presented as mean ± SD of three separate experiments.
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HDL and MSU crystals, because similar results were
obtained when FLS were pretreated with HDL before acti-
vation by MSU crystals (Figure 3a, Ptt.). In the latter set-
ting, the inhibition of CCL2 production tended to be more
pronounced when FLS were pretreated with HDL. To con-
firm that HDL directly affected the FLS stimulation state,
as suggested by results of Figure 3a, we sought to assess the
production of other cytokines and to test another FLS stim-
ulus. As shown in Figure 3b, the MSU crystals-induced
production of IL-8 was inhibited in the presence of HDL
and abolished when FLS were pretreated with HDL. When
FLS were activated by IL-1β, the induced CCL2 production
was inhibited in the presence of HDL in a dose-dependent
manner, the inhibition being more pronounced when cells
were pretreated with HDL (Figure 3c). IL-1β was not
detectable in MSU crystals-activated FLS supernatants
(data not shown), thus ruling out a part of an autocrine loop
of IL-1β, the induction of CCL2 or IL-8 production.
Together, these results establish that HDL directly affected
the FLS activation state. The amount of CCL2 induced by
MSU crystals was very low as compared with that induced
by IL-1β. However, CCL2 concentrations in supernatants of
MSU crystals-activated FLS were sufficient to induce
mononuclear cells migration. This effect was reduced when
FLS were treated or pretreated with HDL (Figure 3d).
The premise that HDL inhibited MSU crystal-induced
CCL2 release by FLS was further confirmed by fluorescent
microscopy. As shown in Figure 4, intracellular CCL2 was
drastically diminished in FLS after activation by MSU crys-
tals (Figure 4b), as compared with resting FLS (Figure 4a).
When FLS were activated by MSU crystals in the presence
of HDL, their fluorescence intensity remained similar to
that of resting FLS (Figure 4a and 4c). To ascertain that all
CCL2 recovered in FLS supernatants was provided by
intracellular stores, the effect of cycloheximide (CHX; that
is, an inhibitor of protein synthesis) was tested. As shown in
Figure 4d, CHX did not affect the production of CCL2
induced by MSU crystals, at least for a period of 48 hours,
demonstrating that protein neosynthesis was not required
for optimal CCL2 release. This strengthened the premise
that CCL2 release was a direct effect of MSU crystals and
not due to an autocrine loop after the synthesis and secre-
tion of a putative cytokine. Together, these results demon-
strate that MSU crystal-activated FLS release CCL2 from
cytoplasm stores, and that this release is inhibited in the
presence of HDL.
MSU crystals induce CCL2 gene transcription, which is 
inhibited in the presence of HDL
Because MSU crystals induced the release of CCL2, it was
important to assess whether cell stimulation induced CCL2
neosynthesis (that is, increased CCL2 mRNA levels), to
replenish intracellular stores after activation. To investigate
the effects of MSU crystals on CCL2 mRNA levels, FLS
were incubated with MSU crystals, and CCL2 transcript
levels were evaluated with real-time quantitative PCR. The
induction of CCL2 gene transcription in FLS activated by
MSU crystals was already detectable after 2-hour stimula-
tion and reached a maximum at 18 hours, with enhance-
ments varying between 3 and 13 times basal levels,
depending on the experiment (not shown). MSU crystal-
induced expression of CCL2 mRNA was inhibited in FLS
stimulated in the presence of HDL (Figure 5). In the
absence of stimulus, HDL did not affect CCL2 mRNA lev-
els. These results suggest that HDL directly acted on FLS to
diminish MSU crystal-induced CCL2 production by inhib-
iting the release of vesicle content and by diminishing the
neosynthesis of the chemokine.
Discussion
This study demonstrates that FLS contain intracellular
stores of CCL2 that are released on activation by MSU
crystals. CCL2 release is accompanied by the induction of
Figure 2 CCL2 is stored in cytoplasmic vesicles in fibroblast-like synoviocytes (FLS). FLS were cultured for 24 hours in the absence (a, c) or pres-
ence (b) of 50 μg/ml monosodium urate (MSU) crystals. Cells were subjected to immunostaining with anti-CCL2 antibodies (a, b) or incubated with 
the second antibody only as a negative control (c), and then analyzed with confocal microscopy, as described in Materials and Methods. Original mag-
nification, ×1,000.Scanu et al. Arthritis Research & Therapy 2010, 12:R23
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g
Figure 3 High-density lipoproteins (HDL) inhibit CCL2 production induced by monosodium urate (MSU) crystals in fibroblast-like synovi-
ocytes (FLS). (a, b) FLS were stimulated (grey columns) or not (white columns) for 24 hours with 50 μg/ml MSU crystals in the presence or absence 
of the indicated concentration of HDL. Alternatively, FLS were pretreated (Ptt.) with the indicated concentration of HDL, washed, and then stimulated 
for 24 hours with 50 μg/ml MSU crystals. Culture supernatants were analyzed for the production of CCL2 (a) and IL-8 (b). Results are presented as mean 
± SD of duplicate determinations and are representative of independent experiments carried out with FLS isolated from three different patients. (c) 
FLS were stimulated (black columns) or not (white columns) with 10 pg/ml IL-1β for 24 hours. Culture supernatants were analyzed for the production 
of CCL2. (d) Culture supernatants of FLS, activated as in (a) and (b), were analyzed for their ability to induce mononuclear cell migration, as described 
in Materials and Methods. Migration induced by culture medium (white column), 10 ng/ml CCL2 (black column), and culture supernatants of FLS ac-
tivated as in (a) and (b) (grey columns). Four fields were counted for the number of migrated cells. Results represent the mean ± SD of the number of 
cells/field in four fields. A representative experiment of three is presented.
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ene transcription, suggesting that MSU crystals might also
trigger CCL2 store refill. Both these processes are inhibited
in the presence of HDL, confirming their antiinflammatory
activities and the part they might play in gout-attack limita-
tion.
MSU crystals directly induced CCL2 production in FLS.
Indeed, although MSU crystals were shown to activate the
NALP3 inflammasome in mononuclear cells, resulting in
IL-1β production [15], this mechanism does not apply to
FLS in which MSU crystals activation does not induce the
release of IL-1β. In addition to the premise that protein neo-
synthesis is not required for CCL2 production, our results
strongly suggest that the effect of MSU crystals in FLS is
not mediated by an autocrine loop of IL-1.
Intracellular stores of CCL2 were previously described in
endothelial cells, where it is stocked in granules different
from intracellular stores of other chemokines [30,31].
Endothelial cells are known to contain small intracellular
granules that may release several inflammatory factors,
including CCL2, more rapidly than the content of Weibel-
Palade bodies [31,32]. Our results suggest that such a pro-
cess may occur in FLS. To our knowledge, it is the first
time that chemokine secretory granules were observed in
FLS. The premise that CCL2 is immediately available in
joints subjected to attacks of inflammatory agents suggests
that in gout, monocytes may precede neutrophil infiltration.
This was previously suggested in the rat air-pouch model,
in which monocyte/macrophage number increases as early
as 2 hours after MSU crystal injection, whereas neutrophils
peak at 4 and 24 hours [33]. Thus, the presence of intracel-
lular stores of CCL2 might participate in the rapid response
of joint cells to MSU crystals, attracting monocytes/mac-
rophages into the tissue in an attempt to eliminate the
inflammatory agent rapidly.
In addition to the release of CCL2 from intracellular
granules, MSU crystals induced CCL2 gene transcription in
human FLS. Noticeably, CCL2 mRNA transcription was
slow and peaked at 18 hours, displaying a 3-fold to 13-fold
increase, as compared with basal levels in resting FLS.
However, the enhancement of CCL2 was not accompanied
by the enhancement of granule numbers at 24 hours.
Because the production of CCL2 was not enhanced after
24-hour activation, these results suggest that the CCL2
transcript is not traduced immediately, and that longer peri-
ods are required to replenish storage granules.
Figure 4 Fibroblast-like synoviocytes (FLS) stimulated by monosodium urate (MSU) crystals in the presence of high-density lipoproteins 
(HDL) retain intracellular CCL2. FLS were stimulated or not with MSU crystals (50 μg/ml) in the presence or absence of the indicated concentration 
of HDL. After 24 hours, cells were fixed and subjected to immunostaining with anti-CCL2 antibodies. (a) Resting FLS; (b, c) FLS stimulated with MSU 
crystals in the absence (b) or presence of HDL (c). Original magnification × 600. (d) FLS were treated (white columns) or not (grey columns) with 10 
μg/ml cycloheximide (CHX) for 30 minutes and then activated for the indicated time with 50 μg/ml MSU crystals. Results represent mean ± SD of three 
independent experiments.Scanu et al. Arthritis Research & Therapy 2010, 12:R23
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The antiinflammatory role of HDL has been widely
described in in vitro as well as in in vivo models of athero-
sclerosis [34,35]. In addition, HDL-associated apo-AI dis-
play antiinflammatory effects in other inflammatory
disorders in which T-cell contact-induced cytokines produc-
tion in monocytes/macrophages is likely to play a part
[23,36]. HDL also potently reduce radical oxygen species
production induced in neutrophils on contact with stimu-
lated T cells [37]. Recently we demonstrated that apo A-I,
HDL, and total cholesterol levels are decreased in plasma,
whereas apo A-I is increased in the synovial fluid of
patients with inflammatory arthritis. The correlation
between synovial fluid/serum apo A-I ratio and both local
and systemic inflammatory indexes suggests the involve-
ment of HDL in the synovial inflammatory process [38].
The mechanisms of HDL antiinflammatory effects were
partly identified. For instance, HDL might hamper the bind-
ing of LPS to its receptor at the cell surface, as reviewed by
Wu et al. [39]. Similarly, it is likely that HDL impede the
interaction between stimulated T cells and monocytes [23].
Here we demonstrate that HDL display antiinflammatory
properties in MSU crystal-induced inflammation by
decreasing the production and expression of CCL2 in
human FLS. Although this study does not elucidate the
mechanism of HDL action, the premise that cell preincuba-
tion with HDL resulted in an increased inhibition of CCL2
production and expression suggests that HDL may act
directly on FLS either by blocking putative MSU crystal
receptors/sensors or by changing the threshold of FLS
response to crystals. The latter hypothesis suggests that
HDL could directly signal FLS, rendering them less sensi-
tive to inflammatory agents. Apolipoproteins, either apo B
or apo E, were shown to dampen crystal-induced neutrophil
activation, a mechanism that might be relevant to gout-
attack resolution [19,20]. Here we show that FLS activated
by MSU crystals produce CCL2 and thus may attract mono-
cytes/macrophages into the joint. Because they inhibit this
process, HDL might contribute to limit a gout attack at its
very beginning by acting on resident FLS, which play a
major part in chronic inflammation and the destruction of
joint tissues [40].
Conclusions
The present results demonstrate that MSU crystals induce
FLS to release CCL2 that is stored in vesicles in resting
conditions. This mechanism is inhibited by HDL, which
may limit the inflammatory process by diminishing CCL2
production and, in turn, monocytes/macrophages recruit-
ment in joints. Although further studies are needed to iden-
tify which signal-transduction pathways are specifically
involved in the activation of FLS by MSU crystals and to
elucidate the mechanism of action of HDL in the limitation
of crystal-induced inflammation, this study confirms the
antiinflammatory functions of HDL, which might contrib-
ute to the resolution of acute gout attack.
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Figure 5 High-density lipoproteins (HDL) diminish monosodium 
urate (MSU) crystal-induced CCL2 transcript levels. Fibroblast-like 
synoviocytes (FLS) were cultured for 18 hours alone or with MSU crys-
tals (50 μg/ml) in the presence or absence of HDL (100 μg/ml), as indi-
cated. Total RNA was prepared as described in Materials and Methods. 
CCL2 mRNA levels were determined with duplex quantitative real-time 
polymerase chain reaction (PCR) analysis of triplicates normalized to 
the levels of the 18S mRNA. The relative expression levels of CCL2 
mRNA are presented as mean ± SD of the percentage of relative CCL2 
mRNA expression. The value of mRNA levels in MSU crystal-stimulated 
FLS (MSU) is arbitrarily considered as 1.0. Results are representative of 
three distinct experiments.
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